Hyperemia
Brimochol PF achieves endpoints in second phase 3 presbyopia trial
Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 pivotal trial, according to a press release from Tenpoint Therapeutics.
Researchers validate clinical scale for early catheter infection detection in hemodialysis
A clinical scale was validated for early detection of infections at the exit site of central venous catheters for hemodialysis in patients with kidney disease, according to a study.
Nyxol meets primary endpoint in trial evaluating reversal of mydriasis
Q&A: Clinicians need to understand effect of hyperemia on patients with glaucoma
Hyperemia, a side effect of some glaucoma medications, may cause patients to pause their treatments, according to a survey conducted by Bausch + Lomb and the Glaucoma Research Foundation.
Weakness, blurred vision in a young woman with headaches
A 28-year-old woman presented to the department of ophthalmology at Lahey Hospital and Medical Center with 2 months of headaches and progressive visual changes in both eyes.
Perspective: I. Paul Singh, MD, on the FDA approval of Durysta
The recent paradigm shift in the treatment of glaucoma moving toward earlier intervention, better managing patient compliance and a refocus on addressing the actual pathology continues to move forward with the approval of Durysta, a 10 µg bimatoprost implant for intracameral administration.
Microdose therapies for myopia, presbyopia being studied
iDose lowers IOP, shows no significant adverse events in phase 2 trial
SAN FRANCISCO — The iDose, a titanium implant from Glaukos for continuous drug delivery, has shown positive phase 2 results and is currently in a phase 3 program, according to a speaker here.
New glaucoma therapies provide options for patients on multiple agents
ORLANDO, Fla. – Fixed combination therapies, new single agents with targeted mechanisms of action, laser surgery and future sustained release technologies may reduce the number of drops glaucoma patients need, Constance O. Okeke, MD, MSCE, said here at the Optometric Glaucoma Society meeting, held prior to the American Academy of Optometry meeting.
VIDEO: New agent reduces hyperemia in dry eye disease
ORLANDO, Fla. – Kala Pharmaceuticals’ KPI-121 0.25% significantly and rapidly reduced conjunctival hyperemia in three clinical trials, Walt Whitley, OD, said here at the American Academy of Optometry meeting.